Dysregulation of T<sub>FH</sub>-B-T<sub>RM</sub> lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer.
Where this comes from
- Record sourced from PubMed, PMID 34663810.
- Also identified by DOI 10.1038/s41467-021-26362-0 and PMC identifier 8523541.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations exhibit an unfavorable response to PD-1 inhibitor through unclear mechanisms. Hypothesizing that EGFR mutations alter tumor-immune interactions, we compare tumor-infiltrating lymphocytes between EGFR mutant (EGFR-MT) and wild type (EGFR-WT) tumors through single-cell transcriptomic analysis. We find that B cells, CXCL13-producing follicular helper CD4<sup>+</sup> T (T<sub>FH</sub>)-like cells, and tissue-resident memory CD8<sup>+</sup> T (T<sub>RM</sub>)-like cells decreased in EGFR-MT tumors. The NOTCH-RBPJ regulatory network, which is vital for persistence of T<sub>RM</sub> state, is perturbed, and the interactions between T<sub>FH</sub> and B cells through the CXCL13-CXCR5 axis disappear in EGFR-MT tumors. Notably, the proportion of T<sub>RM</sub>-like cells is predictive for anti-PD-1 response in NSCLC. Our findings suggest that the impairment of T<sub>FH</sub>-B-T<sub>RM</sub> cooperation in tertiary lymphoid structure formation, accompanied by the dysregulation of T<sub>RM</sub> homeostasis and the loss of T<sub>FH</sub>-B crosstalk, underlies unfavorable anti-PD-1 response in EGFR-MT lung tumors.
Medical subject headings
- ErbB Receptors
- Lung Neoplasms
- Lymphocyte Cooperation